Hydralazine-induced constrictive pericarditis

• Published in: Netherlands journal of medicine Vol. 48; no. 5; pp. 193 - 197
• Main Authors: Franssen, C.F.M., El Gamal, M.I.H., Gans, R.O.B., Hoorntje, S.J.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Alphen aan den Rijn Elsevier B.V 01.05.1996; Van zuiden
• Subjects: Anti-neutrophil cytoplasmic antibodies (ANCA); Antibodies, Antineutrophil Cytoplasmic; Antihypertensive Agents - adverse effects; Antihypertensive Agents - therapeutic use; Autoantibodies - analysis; Autoimmune Diseases - chemically induced; Autoimmune Diseases - physiopathology; Biological and medical sciences; Constrictive pericarditis; Drug toxicity and drugs side effects treatment; Humans; Hydralazine; Hydralazine - adverse effects; Hydralazine - therapeutic use; Hypertension - drug therapy; Male; Medical sciences; Middle Aged; Myeloperoxidase; Pericarditis, Constrictive - chemically induced; Pericarditis, Constrictive - diagnosis; Peroxidase - immunology; Pharmacology. Drug treatments; Thoracotomy; Time Factors; Toxicity: cardiovascular system; Myeloperoxidase; Constrictive pericarditis; Anti-neutrophil cytoplasmic antibodies (ANCA); Hydralazine; Human; Hypertension; Pericardial constriction; Toxicity; Cardiovascular disease; Exploration; Histology; Pericardium; Case study; Pathology; Treatment; Heart disease; Pericardial disease; Antihypertensive agent; Adult
• ISSN: 0300-2977; 1872-9061
• DOI: 10.1016/0300-2977(95)00076-3

A 59-year-old man was diagnosed as having constrictive pericarditis 17 months after a typical hydralazine-induced autoimmune syndrome. This late complication of hydralazine has been reported only once. Ten years later the patient was found to have anti-neutrophil cytoplasmic antibodies directed against myeloperoxidase.